Rafi Hofstein
President & CEO @ Toronto Innovation Acceleration Partners
Jerusalem, Israel
Rafi Hofstein is a seed investor at Toronto Innovation Acceleration Partners in Jerusalem focused on Health Care and Solar. Rafi Hofstein joined MaRS Innovation as President and CEO in June 2009. He is currently member of the board of directors of Life Science Ontario and of Clinical Trials Ontario, as well as a member of the Organizing Committee of the Public Policy Forum on Venture Capital and Innovation (part of the Quebec City Conference) and part of the OntarioHealth Innovation Council (OHIC).Hofstein received his PhD and Master of Science degrees in Life Sciences and Chemistry from the Weizmann Institute of Science in Rehovot, Israel. His Bachelor of Science degree in Chemistry and Physics is from the Hebrew University in Jerusalem.Awards he received while completing post-doctoral training and research at the Harvard Medical School in Boston in the Departments of Biological Chemistry and Neurobiology include the Hereditary Disease Foundation Fellowship in 1982-83, and the Chaim Weizmann Postdoctoral Fellowship in 1980-82.During the 1980s, he held the roles of scientific director of Biotechnological Applications Ltd., and manager R&D and chief of Immunochemistry at the International Genetic Scientific Partnership, organizations that were pivotal in developing Israel’s world-leading biotechnology sector.Hofstein was scientific director of the Israeli office of Ecogen Inc., a subsidiary of Monsanto, for over six years before assuming the role of vice-president, Business Development for Ecogen in Langhorne, Pa.From 1997 to 1999 Hofstein was president of Mindsense Biosystems Ltd., an Israeli company that develops neuropsychiatric immune assays. From 1999 to the present, he has held the position of president and CEO of Hadasit Ltd., the technology transfer company of the Hadassah Medical Organization in Jerusalem. Later on, Hofstein joined Medica Ventures, a lead VC in Israel and served for 10 years as the president and CEO of Hadasit, the commercialization company of Hadassah, the largest teaching hospital in Israel.Hofstein was the founder and served as chair of Hadasit BioHolding Ltd., a publicly-traded holding company (10 start-ups under management) on the Tel Aviv Stock Exchange (TASE) since 2005. Other directorships held on TASE publicly-traded companies include: Bioline RX (drug development); Exalenz (medical devices); and Evogene (agri-bio).He has also served as chairman of BIOMED, Israel’s annual biomedical conference, from 2005 to 2007. In addition, Hofstein is a co-founder and board member of ILSI, the Israeli Life Science Industry Organization, and a co-founder and executive in Israel’s Tech Transfer Network (ITTN).
- Total investments:
- 4
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Rafi Hofstein invests in
Stages Rafi Hofstein invests in
Countries Rafi Hofstein invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (50%)
- Solar 1 (25%)
- Energy 1 (25%)
- Medical 1 (25%)
- Training 1 (25%)
Stage
- Seed 1 (25%)
- Pre-Seed 1 (25%)
- Series A 1 (25%)
- Venture - Series Unknown 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| The solar photovoltaic market is one of the fastest growing energy markets in the world. That growth comes amidst the race to the bottom on cell and module pricing driven by fierce supply side market competition. PV manufacturers can no longer count on economies of scale and incremental process improvements to attain profit in the face ofcompetitive pricing pressures. Manufacturers need to differentiate their product by delivering better performance for the same or lower cost. QD Solar, a University of Toronto spinoff company, will provide this differentiation. | $1.9M / Series A / Feb 13, 2017 | ||
| Fibrocor Therapeutics is focused on developing disease modifying therapeutics in fibrosis.The company has already identified a lead program and will partner with Evotec to develop novel molecules . | $2.1M / Seed / Jan 17, 2017 | ||
| Advances in medical science have introduced the era of personalized medicine for organs. XOR Labs Toronto is a pioneer in this field. We are changing the face of organ transplantation by exponentially increasing the number of donated lungs available for transplantation around the world. | $2.2M / Venture - Series Unknown / Sep 21, 2016 | ||
| OtoSim was developed by a renowned multi-disciplinary team of clinicians, educators, and engineers. Drs. Forte and Campisi recognized the deficiencies that exist in current-day otoscopic training, pioneered the OtoSim device to resolve the problem and proved its value through a scientific study. Enlisting commercialization support from MaRSInnovation and The Hospital for Sick Children (SickKids), the multi-disciplinary team engineered the device and developed the software to create OtoSim | Pre-Seed / Apr 25, 2011 |
Co-Investors
MaRS Innovation (MI) is a commercialization engine that integrates, centralizes and accelerates time to market of the discovery and intellectual property assets from its 15 world-class research institutions. MI’s discovery and innovation pipeline is derived from $1 billion in annual R&D funding. Created as a not-for-profit organizationthrough the Government of Canada’s Center of Excellence for Commercialization and Research program (CECR), MI has raised $50 million from federal and provincial governments, member institutions and industry partners. MI’s vision is to transform the Toronto-based research enterprise into one of world’s most successful commercialization clusters.Through detailed, market facing due diligence, MI identifies opportunities from Canada’s largest academic cluster for further development and commercialization through project management, intellectual property management, investment and technology development. By crossing the innovation gap, MI transforms these opportunities into successful high-value licensing transactions and financeable start-up companies.
Toronto Innovation Acceleration Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Ben Rogers
Director
|
|||
Dominic Jaikaran
Director
|
|||
Mark Zdziebko
Manager
|
|||
Prakash Gowd
Vice President
|
|||
Susanne Staer
Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Rafi Hofstein invest in?
Rafi Hofstein invests primarily in Health Care, Solar and Energy startups, most often at Seed and Pre-Seed stage. Most of the 4 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Rafi Hofstein?
Public channels for Rafi Hofstein include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Rafi Hofstein last invest?
The most recent investment recorded for Rafi Hofstein closed in Feb 2017. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
